comparemela.com

Latest Breaking News On - Critical area pathology - Page 1 : comparemela.com

TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC

Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.

Riccardo lencioniDepartment of surgeryCancers symposiumCritical area pathologyRiccardo lencioniChemoembolization taceUrvalumab imfinziNd bevacizumab avastinHepatocellular carcinomaPhase 3 emerald 1 trial nct03778957

Imfinzi, Avastin, TACE May Set a New Standard of Care in Liver Cancer

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer.

Imfinzi avastinRiccardo lencioniDepartment of surgeryCritical area pathologyAsco gastrointestinal cancers symposiumLiver cancer

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

Riccardo lencioniDepartment of surgeryCritical area pathologyDruvalumab and bevacizumab plus taceHepatocellular carcinomaGastrointestinal cancerGi cancerAsco giTransarterial chemoembolizationPhase 3 emerald 1 trial2024 gastrointestinal cancers symposiumUniversità di pisa

vimarsana © 2020. All Rights Reserved.